Kezar Life Sciences, which is developing small molecule therapeutics to treat autoimmune diseases and cancer, filed on Thursday with the SEC to raise up to $81 million in an initial public offering.
The San Fancisco, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol KZR. Jefferies, Cowen & Company, Wells Fargo Securities and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
